First-ever DehydraTECH-processed tirzepatide from Zepbound to be tested in a swallowed oral format
KELOWNA, BC / ACCESSWIRE / May 23, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has hired a contract research organization ("CRO") to perform the Company's human pilot study #3, (the "Study") which will evaluate a dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulintropic peptide).
The Study will be a randomized, crossover investigation that will compare injected tirzepatide (Zepbound by Eli Lilly) to a compound formulated, DehydraTECH-processed tirzepatide derived from Zepbound and rendered into a capsule to be swallowed. There are two study arms:
- DehydraTECH-tirzepatide swallowed capsules; and,
- Injected Zepbound tirzepatide by Eli Lilly.
Tirzepatide is currently available only in its injected form, Zepbound, by Eli Lilly - it is not available in an FDA-approved oral dosage format. The Study will evaluate whether DehydraTECH-processed tirzepatide, when taken orally, offers any absorption into the human bloodstream and, if so, how much. Human tolerability, pharmacokinetics and blood sugar levels will all be recorded and evaluated in this Study.